Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
PERGOLIDE (PERGOLIDE MESYLATE)
BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
1MG
TABLET
PERGOLIDE (PERGOLIDE MESYLATE) 1MG
ORAL
15G/50G
Prescription
HORSES
Active ingredient group (AIG) number: 0131296001
APPROVED
2013-09-05
PRASCEND® (DIN 02412217) V158770 NC – ADDITIONAL HUMAN WARNINGS DSTS#256903 BIAHCI VERSION DATED 29-NOV-2021 BLISTER LABEL PR PRASCEND® Pergolide (as pergolide mesylate) 1 mg tablets for horses VETERINARY USE ONLY DIN 02412217 Boehringer Ingelheim Animal Health Canada Inc. PR PRASCEND® Comprimés de 1 mg de pergolide (sous forme de mésylate de pergolide) pour les chevaux USAGE VÉTÉRINAIRE SEULEMENT DIN 02412217 Boehringer Ingelheim Santé Animale Canada Inc. (L): EXP: CARTON LABEL Left Flap PR PRASCEND® Pergolide (as pergolide mesylate) 1 mg tablets for horses Comprimés de 1 mg de pergolide (sous forme de mésylate de pergolide) pour les chevaux VETERINARY USE ONLY USAGE VÉTÉRINAIRE SEULEMENT Right Flap L): EXP: Front Panel (English): PR PRASCEND® DIN 02412217 Pergolide (as pergolide mesylate) 1 mg tablets for horses VETERINARY USE ONLY WARNINGS: KEEP OUT OF REACH OF CHILDREN. Prascend® should not be administered by persons who have had adverse reactions to ergotamine or other ergot derivatives. Pregnant or nursing women should wear gloves when administering this product. Prascend® tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. Avoid accidental ingestion and contact with skin or eye. Do not use in horses intended for human consumption. SEE PACKAGE INSERT FOR ADDITIONAL WARNINGS. Net Content: (60) (160) Tablets Boehringer Ingelheim logo PRASCEND® (DIN 02412217) V158770 NC – ADDITIONAL HUMAN WARNINGS DSTS#256903 BIAHCI VERSION DATED 29-NOV-2021 Front Panel (French): PR PRASCEND® DIN 02412217 Comprimés de 1 mg de pergolide (sous forme de mésylate de pergolide) pour les chevaux USAGE VÉTÉRINAIRE SEULEMENT MISES EN GARDE : GARDER HORS DE LA PORTÉE DES ENFANTS. Prascend® ne devrait pas être administré par des personnes ayant déjà eu des réactions indésirables à l’ergotamine ou autres dérivés de l’ergot. Les femmes enceintes ou qui allaitent devraient porter des gants pendant l’a Đọc toàn bộ tài liệu